Navigation Links
Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55
Date:1/26/2009

emerging pipeline.

For the full year, R&D expenses were $2,910 million in 2008 versus $3,064 million in 2007, a decrease of 5 percent. The full year decrease was primarily driven by lower late-stage clinical trial costs, the benefit of our licensing agreement with Takeda and Daiichi Sankyo in Japan, and lower staff-related and discretionary expenses as a result of our restructuring. These decreases were partially offset by an up-front payment under our licensing agreement with Kyowa Hakko as well as higher clinical trial spend for our emerging pipeline.

Selling, General & Administrative (SG&A) expenses increased 7 percent to $1,062 million in the fourth quarter of 2008 versus $990 million in the fourth quarter of 2007 reflecting higher expenses associated with the Wyeth profit share in ENBREL and product promotional expenses partially offset by lower staff-related expenses. The expenses associated with the Wyeth profit share increased 17 percent to $309 million in the fourth quarter of 2008 versus $265 million in the fourth quarter of 2007. Excluding the expenses associated with the Wyeth profit share, adjusted SG&A expenses in the fourth quarter of 2008 increased by 4 percent versus the same quarter last year.

For the full year, SG&A expenses were $3,708 million in 2008 versus $3,382 million in the prior year, an increase of 10 percent. This increase was primarily due to higher expenses associated with the Wyeth profit share, product promotional spending, and staff-related costs. These were partially offset by lower litigation expenses. The expenses associated with the Wyeth profit share increased 21 percent to $1,195 million for the full year 2008 versus $984 million in the prior year. Excluding the expenses associated with the Wyeth profit share, adjusted SG&A expenses for the full year 2008 increased 5 percent versus the full year 2007.

The t
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Related biology technology :

1. Beckman Coulter Announces Fourth Quarter 2008 Earnings to be Released on Monday, February 9, 2009, After Market Closes
2. Amgen Announces Webcast of 2008 Fourth Quarter and Full Year Financial Results
3. Caliper Life Sciences Announces Preliminary 2008 Fourth Quarter and Full Year Revenue Results
4. Cepheid Announces Preliminary 2008 Fourth Quarter and Full Year Revenue Results
5. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
6. BioMed Realty Trust Declares Fourth Quarter 2008 Common Stock and Preferred Stock Dividends
7. Martek Announces Fourth Quarter and FY 2008 Financial Results
8. Martek to Announce Fourth Quarter and Fiscal Year 2008 Results
9. Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results
10. Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year
11. Varian, Inc. Reports Strong Fourth Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Calif. , Jan. 22. 2015  Varian Medical Systems (NYSE: ... software, has been honored for its commitment to sustainability with ... companies. Varian is the highest ranked healthcare equipment company among ... today during the World Economic Forum at Davos, ...
(Date:12/25/2014)... 2014 The report “Service Quality Management ... & Provider Type - Global Advancements, Worldwide Forecasts & ... in-depth analysis and forecasting of revenues. , Browse ... pages and in-depth TOC on “Service Quality Management (SQM) ...
(Date:12/24/2014)... , Dec. 24, 2014  Vermillion, Inc. (Nasdaq:   ... disease, announced today that the Company closed its ... Investment Management, Jack W. Schuler , Birchview ... were $10.5 million, before offering expenses.  The proceeds ...
(Date:12/24/2014)... St. Louis, Missouri (PRWEB) December 23, 2014 ... Swiss biotechnology company, Syngenta, are in the process of being ... consolidated case is In Re: Syngenta AG MIR 162 Corn ... the District of Kansas. , Management of the Syngenta GMO ...
Breaking Biology Technology:Varian Honored Among World's 100 Most Sustainable Corporations 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2
... LAKE, N.J., Aug. 15 Barr,Pharmaceuticals, Inc. (NYSE: ... Barr,Laboratories, Inc., has initiated a challenge of the ... with Warner Chilcott,s Femcon(R),FE (norethindrone and ethinyl estradiol) ... the first to file an Abbreviated New Drug,Application ...
... - Angiotech Pharmaceuticals,Inc. (NASDAQ: ANPI , ... device company, today announced that it has ... Administration (FDA) to begin marketing additional,diameters of ... line. The Quill(TM) SRS PDO is ...
... August 16 /PRNewswire-FirstCall/,-- Santhera Pharmaceuticals (SWX: SANN, ... focus on neuromuscular diseases, and Takeda,Pharmaceutical Company ... European Medicines Agency (EMEA) has accepted the ... Santhera,s lead compound,SNT-MC17 (INN: idebenone, originally developed ...
Cached Biology Technology:Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product 2Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product 3Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line 2Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line 3Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line 4European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreich's Ataxia by Santhera 2European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreich's Ataxia by Santhera 3European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreich's Ataxia by Santhera 4European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreich's Ataxia by Santhera 5European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreich's Ataxia by Santhera 6
(Date:12/17/2014)... and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ) has announced ... Home Button Synaptics Fingerprint Sensor Technology Analysis" report ... Based on a totally different sensing ... first time a fingerprint sensor in its product. ...
(Date:12/17/2014)... Valencell, a leader in performance biometric data sensor technology, ... such as Intel, Jabra, Atlas, and Scosche to develop ... products will be showcased at CES 2015, taking place ... "Our partners choose PerformTek biometrics, because ...
(Date:12/15/2014)... 12, 2014 Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ... Facial Recognition Market 2015-2019" report to their offering. ... Facial recognition is a technology used for the identification ... feature of a person such as nose, jaw edges, ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... ANN ARBOR, Mich.---Oh, the challenges of being a neuron, ... and sensitivity to touch, sound and light, yet constantly ... How on earth are busy nerve cells supposed to ... that information overload? Somehow neurons do manage to ...
... from the University of Adelaide has added to ... warm-blooded and active. Professor Roger Seymour from ... has applied the latest theories of human and animal anatomy ... The results will be published this month in ...
... a mutation in plants that was selected twice - during ... identified as the source of variation in the evolution of ... source of key changes during the domestication of rice. ... and man-made changes was the same," said one of the ...
Cached Biology News:Scientists discover how best to excite brain cells 2Holes in fossil bones reveal dinosaur activity 2Holes in fossil bones reveal dinosaur activity 3Evolution and domestication of seed structure shown to use same genetic mutation 2
HRP Monoclonal-Goat Diluent - 5X Concentrate, 25 mL...
... Turn routine agarose gel electrophoresis into an ... system. This bufferless, pre-cast system is ideal ... restriction digests, and more. Fully automated, robot-compatible, ... E-Gel 96 system makes your high-throughput screening ...
...
Fluorescence Preserving Media, 100 mL...
Biology Products: